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Summary.-The effects of one large single dose of 5-fluorouracil (FU) have been
compared to the same amount given in divided doses daily over a 3- or 5-day period.
Comparison of the effects of single vs fractionated dosage was made on 2 types of
experimental solid tumour with different growth, cell kinetic, histological and
metastasizing properties. The tumour response was essentially the same for both the
single and fractionated dose schedules.
There were marked increases in animal mortality from drug toxicity following
fractionated doses of FU compared to one large single dose. Mortality in animals
with Tumour 3924A increased from 10% following one large single dose to 600/ for
animals given daily fractionated doses for 3 days, and 80o/ for animals given daily
fractionated doses for 5 days. Total marrow reserve was measured by the total DNA
content of tibial marrow. The nadir of 6 days for loss of total tibial marrow DNA
following one large dose of FU was increased to 9 days for both fractionated schedules
of FU. The 3-day delay in recovery of the marrow prevented recovery within the time
frame necessary for animal survival. The inference from these experimental cancer-
treatment studies is that daily fractions of chemotherapeutic agents such as FU
result in increased morbidity and mortality, without benefit in the control of the
solid tumour. The results question the advisability of the clinical practice of initially
giving small daily "loading doses" of proliferation-dependent agents such as FU.
These results emphasize the need for more precise information on the temporal
relationship between the response and recovery of the host and the response and
recovery of the solid tumour. They also emphasize the need for a better clinical
understanding of the time sequence of solid-tumour recovery in relation to the time
sequence of marrow recovery.
"ALTHOUGH 5-fluorouracil (FU) has
been used clinically since 1957, there
presently exists a wide divergence in
opinion among individual investigators,
institutions, and-cooperative groups about
the optimal dosage regimen" (Ansfield
et al., 1977). Initial "loading doses" of FU
and other proliferation-dependent cancer-
chemotherapeutic agents are given daily
or on alternate days and pushed to the
point ofmild toxicity. This approach to the
clinical management of cancer patients
uses, in most instances, host toxicity as
the primary guide for the scheduling ofthe
proliferation-dependent chemotherapy
agents such as FU. Quantitative assess-
ment of tumour response is often difficult
or impossible. It is evident that more pre-
cise information on the temporal relation-
ship between the response and recovery
of the host and the response and recovery
ofthe tumour is needed for a more rational
design of clinical protocols.
Studies on the effects of FU on experi-
mental solid tumours have been carried
out, to determnine quantitatively the
effect of increasing doses of FU on
tumour growth, animal morbidity and
mortality. The ability to evaluate quanti-
tatively the effects of different schedules
of FU on both solid tumour and critical
host organs provides the means for the
concomitant evaluation of the effects of
FU on the tumour in relation to the effectsW. B. LOONEY, M. S. MACLEOD AND H. A. HOPKINS
on the host. Information obtained thus
far suggests that further improvement in
cancer management of solid tumours in
man may be realized, if the temporal
relation between tumour treatment and
patient response is better understood.
This report contains an extension of
these studies, designed to determine the
effects of one large single dose of FU
compared to the same amount ofFU given
in divided doses over 3- or 5-day intervals.
Comparisons have been made on the
quantitative effects of the single vs frac-
tionated doses of FU on both tumour and
host response, as well as animal survival.
These studies have been carried out in 2
solid-tumour lines of the same cell type
but with different growth, cell-kinetic,
histological, and metastasizing properties.
Results from these studies should be
helpful in the continuing efforts to deter-
mine the optimum clinical regimen for
such effective cancer-chemotherapeutic
agents as FU.
MATERIALS AND METHODS
Solid tumour lines.-Repeated cell kinetic
andgrowth studies overthepast 10yearshave
shown Hepatoma 3924A to be stable and
reproducible. Itis anundifferentiated tumour,
and the parenchymal tumour cells are hypo-
tetraploid. The kinetics of cell proliferation
and tumour growth are given in Table IA and
the relative tissue constituents in Table IB.
To determine the relative tissue composition
of the tumour, sections were stained with
Masson-trichrome (Kovacs et al., 1977). This
staining procedure facilitates the recognition
of green-stained connective-tissue elements
and gives good contrast between viable and
necrotic or degenerating tumour tissue.
A major advantage of this tumour line is
that it rarely metastasizes. This permits
studies with the primary, which are related
to the effects of treatment on the tumour,
without the deleterious effects of metastases
on the host. The failure of the tumour to
metastasize may be related to the antigenic
response of the host to the tumour.
Hepatoma H-4-II-E, which metastasizes
to the lungs and axillary nodes, is carried in
our laboratory both in vivo and in vitro.
H-4-1I-E is a poorly differentiated tumour.
The kinetics of cell proliferation and tumour
growth are given in Table IA and the relative
tissue constituents in Table IB.
Animnals.-Inbred ACI-strain rats (Labora-
tory Supply Company, Indianapolis, Ind
and Mammalian Genetics and Animal Pro-
duction Section, National Cancer Institute)
weighing usually 120-140 g were used. Trans-
plants of Hepatoma 3924A were performed
by Dr H. P. Morris, Howard University,
Washington, D.C. The H-4-II-E cells were
grown in tissue culture and 2 x 106 cells were
injected s.c. The rats were caged individually
in an air-conditioned room lighted from 8 a.m.
to 8 p.m. and provided rat chow (Charles
River Laboratories, Wilmington, Mass) and
water ad libitum.
Tumour volume measurements.-Tumour
volumes (mm3) were calculated from measure-
ments of length, width and height on the
assumption that the tumours were hemiellip-
soids in which volume=417r/3. 1/2, .w/2.h/2,
which approximates to 1/2 lwh (Looney
et al., 1976a). Measurements were made
TABLE IA.-Growth and Cell-proliferation Kinetics*
Cell [3H]TdR Actual Potential
Tumour cycle labelling index Growth doubling doubling
line (h) ±s.e. mean fraction time (h) time (h)
3924A 27-4 16-3±0-6 0-65 96 42-0
H-4-II-E 39-1 13-8±0*5 1 00 49 34 - 8
* Looney et al, 1976a.
TABLE IB.-Relative Tumour Tissue Constituents*
Tumour line
3924A
H-4-II-E
Parenchymal
51-1 ±1-5
44-5+2- 8
Necrotic
17-6±0-9
10-4±1 -5
Connective
26 -0±2 -3
5 9±0 7
Blood
5-2±0-8
3853±3 1
* Kovacs et al, 1977. % of cross-section area containing specific tissue type±s.e. mean.
Cell-loss
factor
0 60
0-32
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daily for 2-4 days before treatment and 1-2
weeks after treatment, and during the
period of major changes in tumour growth
rates. They were then measured thrice weekly
until the termination of the experiments.
Experiments were scheduled when animals
could be grouped with a mean tumour volume
of200 mm3 or larger at the time oftreatment.
Marrow evaluation.-At various times after
injection of 150 mg/kg ofFU, groups of 3 rats
each were injected i.p. with 50 HCi thymidine-
(methyl)-3H (sp. act. 3 Ci/mmol) and the rats
killed 1 h later. The marrow was aspirated
from the tibia with cold 0-9o NaCl. DNA
was extracted by heating at 90°C for 20 min
with 5%0 trichloroacetic acid and was meas-
ured by the method of Burton (1956). Calf
thymus DNA (Sigma, St. Louis, Mo) was the
standard. Radioactivity in the nucleic-acid
extracts was measured on a Beckman liquid
scintillation spectrophotometer using external
standardization, aspreviouslydescribed (Hop-
kins et al., 1976).
5-Fluorouracil (FU).-FU (Roche Labora-
tories, Hoffman-La Roche Inc., Nutley, NJ)
prepared in sterile saline was given by i.p.
injection between 8.00 and 8.30 a.m. The
volume injected was 1 ml. Control animals
were injected with saline.
RESULTS
The time sequence of the effects of FU
on the marrow reserve, peripheral blood
and animal survival after single or "split
doses" of 150 mg/kg FU is given in Fig. l.
It has been found in well-defined "split
dose" animal survival studies that rats
recover rapidly and reach 10000 survival
levels when the second dose of FU is
given 10-11 days after the first. All animals
die when the second dose of FU is given
3-4 days after the first. Rapid recovery
occurs, so that all animals survive, if the
second dose is given 9-10 days after the
first (Fig. 1). Marrow reserve is measured
by the depression of the total DNA con-
tent of the tibia. Loss of total DNA of the
bone gives a measure of the total loss of
inarrow cells following treatment. About
9000 of the total marrow cells are lost
between 3 and 6 days after a large single
dose of FU (150 mg/kg) in both normal
rats and those with tumours. There is
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Fi(. 1.-Changes in peripheral white-blood-
cell counts, total tibial marrow DNA, and
survival after a(dministration of 150 mg/kg
FU to ACI rats. For the survival studies the
2nd injections of 150 mg/kg FU were given
at the intervals on the abscissa and each
symbol represents data from 10 to 40 rats.
Data plotted at Time 0, when rats receivedl
a single injection of 150 mg/kg FU. For
tibial marrow and peripheral WBC counts
each symbol is the mean of 3 rats. (Marrow
data normalize(d firom Hopkins et al.,
1976.)
rapid recovery of the marrow reserve
beginning at Day 9, which returns to
normal values by Day 10-11. A similar
pattern occurs in the peripheral blood.
The major difference is that the magni-
tude of depression in the peripheral white
blood counts is only 50%0 ofcontrol values,
whilst the marrow is 100% of control values
at the nadir of depression. The epithelium
of the gastrointestinal tract recovers in
about one half the time needed for the
haemopoietic system (Hopkins etal., 1976).
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after single doses of FU 0 (150 mg/kg) an(l
daily fractionated (loses for 3 days; 0 (3 x
50 mg/kg); and for 5 days J (5 x 30 mg/kg).
Each point is the mean ± s.e. mean for 3
8 10 12 14 16 18 animals, expressed as percent of control.
Control was 0 581 + 0 02 mg/tibial marrow.
Days After Initiation of Treatment
Fi(e. 2. Relative changes in the rate of 3H
incorporation into tibial bone marrow DNA
after single 0 (150 mg/kg) and fractionated
doses of FU given daily for 3 days; 0 (3 x
50 mg/kg) or 5 days E (5 x 30 mg/kg).
Each point, is the mean ± s.e. mean for 3
animals. Control value, 2 * 30±0 * 09 d/min/
mg.
The similarity of the time sequence of
recovery of the marrow and peripheral
blood to the time sequence ofthe return to
100% survival in the split-dose survival
studies indicates that marrow is the
critical organ for animal survival after FU.
The rates of recovery of DNA synthesis
in the marrow of rats without tumours
following one 150 mg/kg dose of FU, 3
daily doses of 50 mg/kg, and 5 daily
doses of 30 mg/kg are shown in Fig. 2.
The rate of DNA synthesis following one
large dose of FU is about twice that of
controls on Day 6 after the initiation of
treatment. The rates of synthesis in the 2
fractionated groups are still depressed
below control groups at this time. How-
ever, rates of DNA synthesis are elevated
at 8 days in all 3 groups, with return to
control levels by Day 17.
The recovery of the marrow reserve, as
measured bv the total DNA content of
tibial marrow, in all 3 groups is shown in
Fig. 3. The nadir for marrow depression
following the large single dose of FU
(150 mg/kg) occurs at Day 6, which is only
200% of control values (Fig. 3; see also
Fig. 1). The nadir for marrow depression
for the 2 fractionated groups is not
reached until Day 9, and is less than 20%
of control values. The recovery of the total
marrow reserve has increased to 4000 of
control values by this time (9 days) in the
single-dose group. It returns to control
values 4 days later, 13 days after the
initiation of treatment. The marrow
reserve of the 2 fractionated-dose groups
had only returned to
-500 of control
values. All animals in the group given
30 mg/kg in 5 daily doses died before 17
days, which accounts for the lack of
information in this group beyond 13 days.
Animal-survival studies in the single
and both fractionated-dose groups with
3924A tumours are shown in Fig. 4 (see
Table II). The 3924A tumour line rarely
metastasizes, so that the animals live for
long periods of time after tumour inocu-
lation. No rats died in the 10-animal
control group. One animal out of 10 died.
5 days after treatment in single-dose
(150 mg/kg) group, a mortality of 100%.
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TABLE II. Single vs Fractionated Doses of 5-Fluorouracil on Animal Survival
and Tumour Growth in H-4-II-E and 3924A
r--
Mean
t,umour
Day 7
Mean
% of tumour
Day 22
Tumour and volume control volume
treatment (mm3) s.e. volume (mm3) ±s.e.
A. H-4-II-E
1. Controls 3,400 ±340 19,700 ±3,100
2. 150 mg/kg x 1 1,400 -1-190 40 16,000 ±1,100
3. 50 mg/kg x 3 1,700 ±250 50 17,400 ±3,200
4. 30 mg/kg x 5t 1,700
B. 3924A
1. Controls 2,700 +380 37,700 - 5,300
2. 150 mg/kg x 1 660 ±80 25 13,000 ± 2,100
3. 50 mg/kg x 3 570 ±100 21 14,900 ±4,800
4. 30 mg/kg x 5 960 ± 130 36 11,400 ±1,600
* Within 2 weeks of FU administration.
t All animals but one dead by Day 7 after initiation of treatment.
Nine out of 15 animals died in the group
which received 50 mg/kg daily for 3 days.
The mean day of death for these animals
was 89+058. The mortality rate increased
to 6000. Twelve out of 15 animals died
in the group which received 30 mg/kg
daily for 5 days. The mean day of death
in this group was 8A4+I1. The mortality
rate in this group increased further to
80%. The experiment was terminated
26 days after the start of treatment.
% of Mean
control day of
volume death
0m
mortality*
21 9±1 9
81 18-6±2-2
88 15-0±3-2
7 9±1 9
34
39
30
None
5 0
8-9±0-8
8 4±1 *1
0
10
60
80
Extensive studies on the effects of single
and "split doses" of FU over a number of
years have shown that almost all animals
which died from the toxic effects of FU
were dead 1-2 weeks after initiation of
treatment. The longest time recorded for
death from toxicity was 18 days. The
study was extended for 1 week after this
to ensure that accurate mortality statistics
on the single and fractionated treated
groups would be obtained.
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FIG. 4.- Survivors (as %) after a single (lose
of FU O (150 mg/kg) and daily fractionated
doses of FU for 3 days A (50 mg/kg x 3)
and 5 days 0 (30 mg/kg x 5) and controls.
Rats were bearing Hepatoma 3924A.
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FIG. 5.--As for Fig. 4 but with rats bearing
H-4-II-E tumours.
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Tumour line H-4-1I-E metastasizes to
the regional lymph nodes and lungs.
The animal-survival studies for the con-
trol and treated groups is shown in Fig. 5.
The mean survival time for untreated
tumour-bearing rats was 2141±1*9 days
after the initiation of treatment. The
tumours reached an average volume of
19,700±3,100 mm3 22 days after initia-
tion of treatment. The mean survival time
for the group given one 150 mg/kg dose of
FU was 18-6i22 days. The mean survival
time was 15 0±3-2 days when the FU
was given 50 mg/kg daily for 3 days. There
was a major reduction in survival time to
7 9±1 9 days when the FU was given at
30 mg/kg daily for 5 days (see Table II).
The effect of FU after the single and
fractionated doses on tumour growth in
3924A is shown in Fig. 6. There is growth
delay for 9-l0 days in all 3 groups.
Tumour volume was 25% of control values
on Day 7 after initiation oftreatment with
the large single dose of FU (Table II).
Tumour volume was 2100 of control
values after the fractionated dose of
50 mg/kg given daily for 3 days and 36%
of control values after the fractionated
dose of 30 mg/kg daily for 5 days. The
values for all 3 groups were similar 15 days
after the initiation of treatment. They
were 23%, 27% and 25% respectively for
the large single dose, the fractionated
dose for 3 days and the fractionated dose
for 5 days. Tumour-volume reduction was
compared in the treated groups when the
growth rates of all 3 had returned to
rates comparable to those in the controls.
The mean tumour volume in the group
given one large dose of FU was 3400 of
control 22 days after the initiation of
treatment. The group given 50 mg/kg
inSr-
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daily for 3 days was 3900 of control and
the group given 30 mg/kg for 5 days was
3000 of control.
The effects of single and fractionated
doses ofFU on tumour growth in H-4-IJ-E
are shown in Fig. 7. Nine ofthe 10 animals
in the group given 30 mg/kg daily for 5
days were dead after tumour measure-
ments 7 days after the start of treatment,
hlence the termination of the growth
curve for this group on Day 6.
Tumour volume was 400% of control
7 days after the start of treatment with
the large single dose of FU, and 5000 of
control 7 days after 50 mg/kg daily for
3 days. The values for the single-dose and
fractionated-dose groups were 4600 and 440 for l4 days and 81% and 88% for
22 days, respectively, after the start of
treatment (Table II).
DISCUSSION
It was found in previous studies in this
series that the total DNA of the tibial
marrow decreased to minimal values of
100 of control 3-6 days after a large
single dose of FU (150 mg/kg) in both
normal and tumour-bearing rats (Hopkins
et al., 1976). These initial findings have
been confirmed in this study.
The major difference in the depression
of the total marrow DNA after the single
dose and fractionated doses of3- and 5-day
periods is in its duration. The nadir for the
marrow depression following the 3- and 5-
fraction schedules is increased from 6 days
for the single dose to 9 days for the
fractionated doses. These results also indi-
cate that peripheral white-cell counts, the
major clinical indicator for drug toxicity,
underestimate the depression of marrow
during cancer chemotherapy.
Fractionation over the 3- or 5-day
period prevents marrow recovery within
the time necessary for animal survival.
This delay in recovery increased the
mortality rates from 10% in the large
single-dose FU group to 60% for the 3
daily fractionated groups and 80% for the
5 daily fractionated groups, in animals
5
with 3924A tumours. The increased animal
mortality following fractionated FU is
more dramatic in rats with H-4-IJ-E
tumours. The study on the fractionated
dose of FU of 30 mg/kg daily for 5 days
had to be discontinued because 9/10 ani-
mals were dead 7 days after treatment.
The mean survival time after the initia-
tion of treatment was reduced to 79+ 1±9
days from 211 +1±9 days for the controls
and 1856+2 2 days for the group which had
one large dose of FU.
It is evident that giving fractionated
doses daily over either a 3- or 5-day
period results in a marked increase in
animal mortality. It is also evident that
no increase in control of tumour growth
occurs relative to a single FU dose. The
similar results from these studies in two
experimental solid tumours with markedly
different animal-survival, growth, cell-
kinetic, and morphological characteristics
raises the question of the validity of the
clinical practice of giving small daily
"loading doses" of cellular proliferation-
dependent agents such as FU. The infer-
ence from these experimental cancer-
treatment studies is that daily fractions
of chemotherapeutic agents such as FU
increase morbidity and mortality without
therapeutic benefit in control of the solid
tumour.
The in vitro studies by Wolberg and
Ansfield (1971) demonstrated a signi-
ficantly greater antitumour effect with the
highest concentration of FU on human
tumour slices than with lower concentra-
tions. The feasibility of using large single
doses ofFU at intervals issupportedbythe
clinical experience of Bagley (1975).
Previous experiments in our series have
demonstrated increasing tumour-volume
reduction with increasing dose of FU over
the first segment of a dose-response curve.
Increasing the dose beyond 150 mg/kg
resulted in lower tumour-volume reduc-
tion with increasing doses of FU. A dose
of 150 mg/kg FU was chosen for these
experiments because it was near the end of
the decreasing segment of the dose-
response curve and it resulted in an LD10
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for animal survival. Tumour volumes in
3924A 7 days after a single dose of FU
were 69-7±11-7; 60-6±10A4; 39'1+5-8;
31-4±9-8 and 51'7±9-7% of control
values for 50, 100, 150,200 and 250 mg/kg
doses (Looney, et al., 1976b, c). In these
experiments, the marrow recovery time
after a single 50 mg/kg dose of FU is
7-8 days. Increasing the dose to 100 or
150 mg/kg prolongs the marrow recovery
time to 10-11 days. Thus, one third the
FU dose (50 mg/kg) requires two thirds
the recovery time for dose 150 mg/kg
(Hopkins et al., 1976).
We have other studies which show that
the maximum rate of change of tumour
volume occurs shortly after the recovery
of the host from the effects of FU. The
growth rates of both tumour lines return
to rates comparable to controls 11-12 days
after treatment with FU. This is also the
time of recovery of the marrow for the
large single dose ofFU. Sequential therapy
every 11-12 days with FU permits the
optimum sequential utilization of FU for
control of tumour growth following host
recovery from the previous treatment
series.
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